Chronic Obstructive Pulmonary Disease Market
Market
Research Future (MRFR) has published a research report about the global chronic
obstructive pulmonary disease (COPD) market that measures huge elevation in
this market between 2016 and 2022. This report provides a detailed analysis of
market structure with the forecast for next years and provides insights into
factors affecting the market growth. Analyzing the market on the basis of
various factors, it evaluates the market with current market size and future
potential regarding growth. Profiling various key players in the market, the
report discusses their activities and observes competitive developments like
joint ventures, mergers and acquisitions, new product developments, strategic
alliances, and research and developments (R & D).
The
global chronic obstructive pulmonary disease market has been segmented into
medicines, treatments, types, and lastly region. On the basis of medicines,
this market has been segmented into antibiotics, bronchodilators, combination
inhalers, inhaled steroids, oral steroids, phosphodiesterase-4 inhibitors, and
theophylline. Antibiotics are useful for fighting bacterial infections.
Bronchodilators are medications that open (dilate) the airways (bronchial
tubes) of the lung by relaxing bronchial muscles. They allow people with
difficulty in breathing to breathe better. A combination inhaler combines two
kinds of medicine in one device. Usually, in a combination inhaler, one
medicine is corticosteroid while the other is a bronchodilator. Advair Diskus,
Breo, Dulera, and Symbicort are some examples of combination inhalers. Some
examples of inhaled steroids include Arnuity Ellipta, Flovent, Pulmicort, Qvar,
and Symbicort are some examples of inhaled steroids. Oral steroids are the
non-narcotic type of powerful prescription medication. Commonly called as a
PDE4 inhibitor, phosphodiesterase type 4 inhibitor, is a drug used to block the
degradative action of phosphodiesterase 4 (PDE4).
The
treatment-based segmentation of market comprises of oxygen therapy, lung
transplant, bullectomy and others. Bullectomy is the surgical process for the
removal of a bulla, which is a dilated air space in the lung parenchyma. A
bulla measures more than 1 cm. Bulla that occupies more than 30% of the
hemithorax is called giant bulla. Bulla is the most common cause of COPD. In
oxygen therapy, oxygen is used for medical treatment. Lung transplant is a
medical process where a permanently damaged lung of a patient is removed, and a
healthy lung from another person is planted into the body of the patient. By
types, the global COPD market has been segmented into chronic bronchitis and
emphysema. Chronic Bronchitis (CB) is defined as a chronic cough and sputum
production for at least 3 months a year for 2 consecutive years. Emphysema is a
lung condition that causes shortness of breath.
The
regional segmentation of global chronic obstructive pulmonary disease market
covers The Americas (North America & South Americas), Europe, Asia Pacific,
and Middle East & Africa (MEA). Among the Americas, North America is the
bigger market for COPD, than South America due to advanced medical facilities
and more investment in this region, the biggest local markets are the United
States of America (USA) and Canada. North America is the largest market among
all regional markets.
Due
to the reasons same as the Americas, Western Europe is the bigger market, than
Eastern Europe. Although the market in whole Europe is decent and steady in
Western Europe, the cream of Europe market in France, Germany, Italy, Spain,
and the United Kingdom (UK). Europe is the second largest market for COPD.
In
the Asia Pacific region, the market is growing due to the high density of
population and improving medical facilities in some countries of this region.
During the forecast period, Asia Pacific is expected to be the fastest growing
market for COPD. The biggest markets in the Asia Pacific are Australia, China,
India, Japan, and South Korea, followed by the rest of the Asia Pacific. In the
MEA region, the market is small due to poor or limited infrastructure and less
investment in health care. However, due to hookah smoking, the number of people
suffering from COPD is sizable. In this region, the biggest markets are Kuwait,
Oman, Saudi Arabia, United Arab Emirates (UAE) and Qatar.
Access
Report @ https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612
Key
Players
The
key players in global COPD market are Abbott (USA), AstraZeneca (UK), Dr.
Reddy’s Laboratories Ltd (India), F. Hoffmann-La Roche Ltd (Switzerland), GSK
(UK), Merck (USA), Novartis AG (Switzerland), and Pfizer Inc (USA).
No comments:
Post a Comment